1. Home
  2. RGEN vs CORT Comparison

RGEN vs CORT Comparison

Compare RGEN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • CORT
  • Stock Information
  • Founded
  • RGEN 1981
  • CORT 1998
  • Country
  • RGEN United States
  • CORT United States
  • Employees
  • RGEN N/A
  • CORT N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • CORT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RGEN Health Care
  • CORT Health Care
  • Exchange
  • RGEN Nasdaq
  • CORT Nasdaq
  • Market Cap
  • RGEN 8.0B
  • CORT 7.5B
  • IPO Year
  • RGEN N/A
  • CORT N/A
  • Fundamental
  • Price
  • RGEN $127.47
  • CORT $72.27
  • Analyst Decision
  • RGEN Buy
  • CORT Strong Buy
  • Analyst Count
  • RGEN 12
  • CORT 4
  • Target Price
  • RGEN $170.40
  • CORT $142.00
  • AVG Volume (30 Days)
  • RGEN 685.0K
  • CORT 1.6M
  • Earning Date
  • RGEN 07-29-2025
  • CORT 07-28-2025
  • Dividend Yield
  • RGEN N/A
  • CORT N/A
  • EPS Growth
  • RGEN N/A
  • CORT 8.36
  • EPS
  • RGEN N/A
  • CORT 1.14
  • Revenue
  • RGEN $650,429,000.00
  • CORT $685,446,000.00
  • Revenue This Year
  • RGEN $13.93
  • CORT $35.83
  • Revenue Next Year
  • RGEN $14.35
  • CORT $35.24
  • P/E Ratio
  • RGEN N/A
  • CORT $63.26
  • Revenue Growth
  • RGEN 4.88
  • CORT 30.93
  • 52 Week Low
  • RGEN $102.97
  • CORT $29.42
  • 52 Week High
  • RGEN $182.52
  • CORT $117.33
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 54.11
  • CORT 49.68
  • Support Level
  • RGEN $121.44
  • CORT $68.52
  • Resistance Level
  • RGEN $131.43
  • CORT $75.95
  • Average True Range (ATR)
  • RGEN 4.47
  • CORT 2.66
  • MACD
  • RGEN 0.61
  • CORT -0.13
  • Stochastic Oscillator
  • RGEN 74.57
  • CORT 42.13

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Share on Social Networks: